{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:32:15Z","timestamp":1738819935408,"version":"3.37.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Histol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10735-024-10313-2","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:17:33Z","timestamp":1733293053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells"],"prefix":"10.1007","volume":"56","author":[{"given":"Mohammadreza","family":"Gholamrezapour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raziyeh","family":"Taghizadeh Ghavamabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Mohsen","family":"Taghavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samereh","family":"Dehghani Soltani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Shabanizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Vazirinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Taghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"12","key":"10313_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/children5120169","volume":"5","author":"R Alfani","year":"2018","unstructured":"Alfani R, Vassallo E, De Anseris A, Nazzaro L, D\u2019acunzo I, Porfito C et al (2018) Pediatric fatty liver and obesity: not always justa matter of non-alcoholic fatty liver disease. Children 5(12):169","journal-title":"Children"},{"issue":"7","key":"10313_CR2","first-page":"1198","volume":"54","author":"MH Ali","year":"2016","unstructured":"Ali MH, Messiha BA, Abdel-Latif HA (2016) Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol 54(7):1198\u20131208","journal-title":"Pharm Biol"},{"issue":"7","key":"10313_CR3","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.4254\/wjh.v14.i7.1382","volume":"14","author":"J Aljabban","year":"2022","unstructured":"Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H et al (2022) Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 14(7):1382\u20131397","journal-title":"World J Hepatol"},{"issue":"13","key":"10313_CR4","doi-asserted-by":"publisher","first-page":"10718","DOI":"10.3390\/ijms241310718","volume":"24","author":"M Alonso-Pe\u00f1a","year":"2023","unstructured":"Alonso-Pe\u00f1a M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, Santos-Laso A, Arias-Loste MT et al (2023) Innovative therapeutic approaches in non-alcoholic fatty liver disease: when knowing your patient is key. Int J Mol Sci 24(13):10718","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10313_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"F Bessone","year":"2019","unstructured":"Bessone F, Razori MV, Roma MG (2019) Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 76(1):99\u2013128","journal-title":"Cell Mol Life Sci"},{"key":"10313_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0438-7","author":"S Breher-Esch","year":"2018","unstructured":"Breher-Esch S, Sahini N, Trincone A, Wallstab C, Borlak J (2018) Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease. BMC Med Genom. https:\/\/doi.org\/10.1186\/s12920-018-0438-7","journal-title":"BMC Med Genom"},{"issue":"1","key":"10313_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/138920008783331086","volume":"9","author":"MT Donato","year":"2008","unstructured":"Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9(1):1\u201311","journal-title":"Curr Drug Metab"},{"key":"10313_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, Scheja L (2021) Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 50:101238","journal-title":"Mol Metab"},{"issue":"4","key":"10313_CR9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5114\/ceh.2018.80128","volume":"4","author":"J Heil","year":"2018","unstructured":"Heil J, Schultze D, Schemmer P, Bruns H (2018) N-acetylcysteine protects hepatocytes from hypoxia-related cell injury. Clin Exp Hepatol 4(4):260\u2013266","journal-title":"Clin Exp Hepatol"},{"key":"10313_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ncomms1001","volume":"1","author":"D Herranz","year":"2010","unstructured":"Herranz D, Mu\u00f1oz-Martin M, Ca\u00f1amero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O et al (2010) Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1:3","journal-title":"Nat Commun"},{"issue":"18","key":"10313_CR11","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 75(18):3313\u20133327","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10313_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/ijms21041525","volume":"21","author":"T Kanda","year":"2020","unstructured":"Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M (2020) Molecular mechanisms: connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma. Int J Mol Sci 21(4):1525","journal-title":"Int J Mol Sci"},{"key":"10313_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00554","author":"S Kaur","year":"2019","unstructured":"Kaur S, Nag A, Gangenahalli G, Sharma K (2019) Peroxisome proliferator activated receptor gamma sensitizes non-small cell lung carcinoma to gamma irradiation induced apoptosis. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2019.00554","journal-title":"Front Genet"},{"issue":"4","key":"10313_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jgr.2017.04.010","volume":"42","author":"GW Kim","year":"2018","unstructured":"Kim GW, Jo HK, Chung SH (2018) Ginseng seed oil ameliorates hepatic lipid accumulation in vitro and in vivo. J Ginseng Res 42(4):419\u2013428","journal-title":"J Ginseng Res"},{"issue":"28","key":"10313_CR15","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","volume":"20","author":"S Milic","year":"2014","unstructured":"Milic S, Lulic D, Stimac D (2014) Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 20(28):9330\u20139337","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10313_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.molimm.2015.06.001","volume":"67","author":"SM Moore","year":"2015","unstructured":"Moore SM, Holt VV, Malpass LR, Hines IN, Wheeler MD (2015) Fatty acid-binding protein 5 limits the anti-inflammatory response in murine macrophages. Mol Immunol 67(2):265\u2013275","journal-title":"Mol Immunol"},{"issue":"1","key":"10313_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/ijms21010265","volume":"21","author":"A Nagappan","year":"2019","unstructured":"Nagappan A, Kim JH, Jung DY, Jung MH (2019) Cryptotanshinone from the salvia miltiorrhiza bunge attenuates ethanol-induced liver injury by activation of AMPK\/SIRT1 and Nrf2 signaling pathways. Int J Mol Sci 21(1):265","journal-title":"Int J Mol Sci"},{"issue":"48","key":"10313_CR18","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.3748\/wjg.15.6017","volume":"15","author":"V Nobili","year":"2009","unstructured":"Nobili V, Alisi A, Raponi M (2009) Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 15(48):6017\u20136022","journal-title":"World J Gastroenterol"},{"key":"10313_CR19","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.033530","author":"M Parafati","year":"2018","unstructured":"Parafati M, Kirby RJ, Khorasanizadeh S, Rastinejad F, Malany S (2018) A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. Disease Models Mech. https:\/\/doi.org\/10.1242\/dmm.033530","journal-title":"Disease Models Mech"},{"issue":"32","key":"10313_CR20","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.3748\/wjg.v29.i32.4831","volume":"29","author":"L Petagine","year":"2023","unstructured":"Petagine L, Zariwala MG, Patel VB (2023) Non-alcoholic fatty liver disease: immunological mechanisms and current treatments. World J Gastroenterol 29(32):4831\u20134850","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10313_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W et al (2022) Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 22(1):63","journal-title":"BMC Endocr Disord"},{"issue":"10290","key":"10313_CR22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212\u20132224","journal-title":"Lancet"},{"issue":"4","key":"10313_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9(4):327\u2013338","journal-title":"Cell Metab"},{"key":"10313_CR24","doi-asserted-by":"publisher","first-page":"5310961","DOI":"10.1155\/2018\/5310961","volume":"2018","author":"M Raffaele","year":"2018","unstructured":"Raffaele M, Barbagallo I, Licari M, Carota G, Sferrazzo G, Spampinato M et al (2018) N-acetylcysteine (NAC) ameliorates lipid-related metabolic dysfunction in bone marrow stromal cells-derived adipocytes. Evid Based Complement Altern Med 2018:5310961","journal-title":"Evid Based Complement Altern Med"},{"issue":"4","key":"10313_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-0028-1091986","volume":"28","author":"N Rafiq","year":"2008","unstructured":"Rafiq N, Younossi ZM (2008) Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 28(4):427\u2013433","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10313_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189856","volume":"13","author":"T Shi","year":"2018","unstructured":"Shi T, Yang X, Zhou H, Xi J, Sun J, Ke Y et al (2018) Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis. PLoS ONE 13(1):e0189856","journal-title":"PLoS ONE"},{"issue":"7","key":"10313_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/ph17070895","volume":"17","author":"Y Sun","year":"2024","unstructured":"Sun Y, Zhou W, Zhu M (2024) Serum metabolomics uncovers the mechanisms of inulin in preventing non-alcoholic fatty liver disease. Pharmaceuticals (Basel) 17(7):895","journal-title":"Pharmaceuticals (Basel)"},{"key":"10313_CR28","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.2147\/DDDT.S109473","volume":"10","author":"R Taghizadeh","year":"2016","unstructured":"Taghizadeh R, Taghipour Z, Karimi A, Shamsizadeh A, Taghavi MM, Shariati M et al (2016) The expression of HoxB5 and SPC in neonatal rat lung after exposure to fluoxetine. Drug des Develop Ther 10:3323\u20133329","journal-title":"Drug des Develop Ther"},{"issue":"8","key":"10313_CR29","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1002\/fsn3.4176","volume":"12","author":"H Tan","year":"2024","unstructured":"Tan H, Mi N, Tong F, Zhang R, Abudurexiti A, Lei Y et al (2024) Lactucopicrin promotes fatty acid \u03b2-oxidation and attenuates lipid accumulation through adenosine monophosphate-activated protein kinase activation in free fatty acid-induced human hepatoblastoma cancer cells. Food Sci Nutr 12(8):5357\u20135372","journal-title":"Food Sci Nutr"},{"key":"10313_CR30","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA et al (2020) The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 2020:3920196","journal-title":"J Diabetes Res"},{"issue":"4","key":"10313_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/dc.21390","volume":"39","author":"Y Wang","year":"2011","unstructured":"Wang Y, Goulart RA, Pantanowitz L (2011) Oil red O staining in cytopathology. Diagn Cytopathol 39(4):272\u2013273","journal-title":"Diagn Cytopathol"},{"issue":"6","key":"10313_CR32","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3892\/etm.2014.2019","volume":"8","author":"F Wang","year":"2014","unstructured":"Wang F, Liu S, Shen Y, Zhuang R, Xi J, Fang H et al (2014) Protective effects of N-acetylcysteine on cisplatin-induced oxidative stress and DNA damage in HepG2 cells. Exp Ther Med 8(6):1939\u20131945","journal-title":"Exp Ther Med"},{"key":"10313_CR33","first-page":"4583","volume":"24","author":"H Wang","year":"2018","unstructured":"Wang H, Wang Y, Xia T, Liu Y, Liu T, Shi X et al (2018) Pathogenesis of abnormal hepatic lipid metabolism induced by chronic intermittent hypoxia in rats and the therapeutic effect of N-acetylcysteine. Med Sci Monit Int Med J Exp Cli Res 24:4583\u20134591","journal-title":"Med Sci Monit Int Med J Exp Cli Res"},{"key":"10313_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.plipres.2015.05.002","volume":"59","author":"J Willebrords","year":"2015","unstructured":"Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B et al (2015) Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res 59:106\u2013125","journal-title":"Prog Lipid Res"},{"issue":"9","key":"10313_CR35","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/ijms19092563","volume":"19","author":"JP Yang","year":"2018","unstructured":"Yang JP, Shin JH, Seo SH, Kim SG, Lee SH, Shin EH (2018) Effects of antioxidants in reducing accumulation of fat in hepatocyte. Int J Mol Sci 19(9):2563","journal-title":"Int J Mol Sci"},{"key":"10313_CR36","doi-asserted-by":"publisher","first-page":"1186582","DOI":"10.3389\/fphar.2023.1186582","volume":"14","author":"K Yang","year":"2023","unstructured":"Yang K, Kim HH, Shim YR, Ryu T, Kim CW (2023) Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease. Front Pharmacol 14:1186582","journal-title":"Front Pharmacol"},{"issue":"5","key":"10313_CR37","first-page":"4737","volume":"14","author":"H Zhou","year":"2017","unstructured":"Zhou H, Shi T, Yan J, Chen X, Liao L, Zhao S et al (2017) Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease. Exp Ther Med 14(5):4737\u20134744","journal-title":"Exp Ther Med"}],"container-title":["Journal of Molecular Histology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-024-10313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10735-024-10313-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-024-10313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:28:14Z","timestamp":1738808894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10735-024-10313-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10313"],"URL":"https:\/\/doi.org\/10.1007\/s10735-024-10313-2","relation":{},"ISSN":["1567-2379","1567-2387"],"issn-type":[{"type":"print","value":"1567-2379"},{"type":"electronic","value":"1567-2387"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"11 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27"}}